Generic placeholder image

CNS & Neurological Disorders - Drug Targets


ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Monoclonal Antibodies as Pharmacokinetic Antagonists for the Treatment of (+)-Methamphetamine Addiction

Author(s): S. Michael Owens, William T. Atchley, Michael D. Hambuchen, Eric C. Peterson and W. Brooks Gentry

Volume 10, Issue 8, 2011

Page: [892 - 898] Pages: 7

DOI: 10.2174/187152711799219370

Price: $65


Developing specific medications to treat (+)-methamphetamine (METH) addiction is a difficult challenge because METH has multiple sites of action that are intertwined with normal neurological function. As a result, no small molecule medication for the treatment of METH addiction has made it through the FDA clinical trials process. With the invention of a new generation of proteinbased therapies, it is now possible to consider treating drug addiction by an entirely different approach. This new approach is based on the discovery of very high affinity anti-METH monoclonal antibodies (mAbs), which are non-addictive and antagonize METH effects from the blood stream without entering the brain. Due to a very long biological half-life, anti-METH mAbs would only need to be administered once every 2-4 weeks, aiding in patient compliance. As a relapse prevention medication, anti-METH mAbs could reduce or prevent the rewarding effects of a relapse to METH use and thereby improve a patient's probability of remaining in therapy and recovering from their addiction. In this review, we discuss the discovery process of anti-METH mAbs, with a focus on the preclinical development leading to high affinity anti-METH mAb antagonists.

Keywords: Addiction, Amphetamines, monoclonal antibodies, pharmacokinetics, rat, vaccines, METH, cognitive behavioral therapy, psychosis, MAB6H4, PCKN

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy